To address the growing use of ad blockers we now use affiliate links to sites like Amazon.com, streaming services, and others. Affiliate links help sites like QualityCounts.com stay open. Affiliate links cost you nothing but help me support my family. We do not allow paid reviews on this site. As an Amazon Associate I earn from qualifying purchases.  Also, you can donate  to ben@qualitycounts.com via Zelle or PayPal.  Click here for the PayPal QR.  Click here for Bitcoin QR code or Bitcoin address: 39muDw6WpQV8j6EdA8eUBvT5iFDiVpVpiE
Home ReliableRXPharmacy Past Newsletters Amazon.com Contact
 Sign-up for newsletter 
 Newsletter Archive
 Newsletter via RSS Feed
 Research on Supplements
 Health Conditions
 Anti-aging Recommendations
 Insulin and Aging
 QualityCounts.com in Time
 Longevity Affiliates:

Home > Health Condition > Alzheimer's Disease > Aduhelm (aducanumab)

Aduhelm (aducanumab)

Related Topics:

News & Research:

  • Aducanumab for Alzheimer's Gets Thumbs Down in Europe - Medscape, 12/17/21 - "The EMA committee noted that while aducanumab reduces amyloid beta in the brain, the link between this effect and clinical improvement had not been established ... The committee also felt that results of the main studies assessing the drug were "conflicting and did not show overall that Aduhelm was effective at treating adults with early stage Alzheimer's disease.""
  • Potential new treatment for Alzheimer’s disease would be relatively cheap - 11/30/21 - "the researchers fed the model mice with diazoxide -- a drug that activates the KATP channel -- and tested their memory. They found that while the untreated Alzheimer's disease model mice exhibited their characteristically poor memory, the treated model mice performed just as well as normal mice. A look at the brains of the treated mice showed that they lacked the hallmark Aβ plaques ... Our findings point directly to a potential way of preventing and treating Alzheimer's disease ... On top of that, compared with Aβ-targeting immunotherapy, such as the drug aducanumab, which was recently approved by the FDA, synthetic agonists for the KATP channel are less expensive and would be more acceptable to aging societies around the world" - Note: Aduhelm (aducanumab) is the one that costs $56,000 per year and is the reason Medicare premiums went up.  It reduces the amyloid β peptide but doesn't seem to reduce Alzheimer's.  Diazoxide sounds like it's got side-effects that seniors don't want to mess with.
    • Diazoxide - Wiki - "Common side effects include high blood sugar, fluid retention, low blood platelets, a fast heart rate, increased hair growth, and nausea.[2] Other severe side effects include pulmonary hypertension and heart failure.[2] It is chemically similar to thiazide diuretics.[2] It works by decreasing insulin release from the pancreas and increasing glucose release by the liver."
  • A new Alzheimer's drug brings hope, controversy - CBS Sunday Morning, 11/28/21
  • Aduhelm, priced at $56,000 a year, is a key factor driving up Medicare premiums - CNN, 11/16/21